Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Receivables for 5 consecutive years, with $12.1 million as the latest value for Q2 2024.

  • Quarterly Receivables changed N/A to $12.1 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Jun 2024, changed N/A year-over-year, with the annual reading at $2.2 million for FY2023, N/A changed from the prior year.
  • Receivables for Q2 2024 was $12.1 million at Janux Therapeutics, up from $4.4 million in the prior quarter.
  • The five-year high for Receivables was $12.1 million in Q2 2024, with the low at $400000.0 in Q2 2021.
  • Average Receivables over 5 years is $4.0 million, with a median of $2.2 million recorded in 2023.
  • Peak annual rise in Receivables hit 450.62% in 2024, while the deepest fall reached 450.62% in 2024.
  • Over 5 years, Receivables stood at $8.0 million in 2020, then crashed by 95.0% to $400000.0 in 2021, then grew by 25.0% to $500000.0 in 2022, then surged by 332.2% to $2.2 million in 2023, then surged by 457.89% to $12.1 million in 2024.
  • According to Business Quant data, Receivables over the past three periods came in at $12.1 million, $4.4 million, and $2.2 million for Q2 2024, Q1 2024, and Q4 2023 respectively.